US Patent

US8550073 — Nasal delivery

Formulation · Assigned to Optinose AS · Expires 2029-10-22 · 3y remaining

Vulnerability score 31/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a nasal delivery device and method for delivering a substance, such as a medication, to a nasal cavity of a subject.

USPTO Abstract

A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece unit ( 20, 24 ) including a nosepiece ( 17 ) for fitting to a nostril of a subject and a nozzle ( 45 ) through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity, wherein at least a tip element of the nosepiece has, at least in one configuration, an elongate lateral section which has a longer dimension in a first, sagittal direction than a second direction orthogonal to the sagittal direction, such that, when the nosepiece is inserted in the nasal cavity of the subject, the longer dimension of the nosepiece acts to engage lower and upper surfaces of the nasal cavity, preferably at the nasal valve, and expand the same in the sagittal plane; and a delivery unit ( 43, 49, 51 ) for delivering substance through the nozzle of the nosepiece.

Drugs covered by this patent

Patent Metadata

Patent number
US8550073
Jurisdiction
US
Classification
Formulation
Expires
2029-10-22
Drug substance claim
No
Drug product claim
Yes
Assignee
Optinose AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.